GoldenGolden
Advanced Search
Celgene

Celgene

Celgene discovers, develops and commercializes innovative therapies to treat cancer and immune-inflammatory-related diseases.

Company Overview

Celgene Corporation is an American biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey and was founded in 1986 by Robert Harris and Sol Barer. The company's major product is Revlimid (lenalidomide), in combination with dexamethasone for the treatment of multiple myeloma patients. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk Myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Vidaza is approved for the treatment of patients with MDS. Celgene Cellular Therapeutics, a subsidiary, is a public cord blood bank.

There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), pancreatic cancer, non-small lung cancer, and melanoma.

History

  • In 1986, Robert Hariri and Sol Barer founded Celgene, originally a unit of the Celanese Corporation. It was spun off as an independent company following the merger of Celanese Corporation with American Hoechst Corporation.
  • In August 2000, Celgene acquired Signal Pharmaceuticals, Inc.
  • In December 2002, Celgene acquired Anthrogenesis. In March 2008, Celgene closed its $2.9 billion acquisition of Pharmion Corporation.
  • In December 2009, Celgene announced the acquisition of Gloucester Pharmaceuticals.
  • In June 2010 Celgene Corporation and Abraxis BioScience Inc. jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience.
  • In January 2012, Celgene and Avila Therapeutics, Inc., a privately held biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics, Inc.
  • In 2014, Celgene and OncoMed Pharmaceuticals entered into a cancer stem cell therapeutic development agreement encompassing Demcizumab and five other biologics from OncoMed's pipeline.
  • Also in 2014, Sutro Biopharma entered into a strategic collaboration and option agreement with Celgene Corporation to discover and develop multispecific antibodies and antibody drug conjugates (ADCs).
  • In April 2015, Celgene announced it would commence a collaboration with Astrazeneca, worth $450 million.
  • In June 2015 Celgene announced it had licensed Lyceras RORgamma agonist portfolio for up to $105 million.
  • In July 2015, the company announced it would acquire Receptos for $7.2 billion in a move to strengthen the company's inflammation and immunology areas.
  • In May 2016, the company announced it would launch a partnership with Agios Pharmaceuticals, developing metabolic immuno-oncology therapies.
  • In October, the company acquired EngMab AG for $600 million.
  • In January 2017, the company announced it would acquire Delinia for $775 million, increasing the company's autoimmune disease therapy offerings.
  • In January 2018, Celgene announced it would acquire Impact Biomedicines for $7 billion. In the same month, the company announced it would acquire Juno Therapeutics for $9 billion.
Products

Celgene Corporation discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company’s products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; bluebird bio, Inc.; Lycera Corp.; Juno Therapeutics, Inc.; and EXSCIENTIA LTD.

Investments

Celgene has acquired 14 organizations. One of their acquisitions was Juno Therapeutics on Jan 22, 2018. They acquired Juno Therapeutics for $9B. The intellectual property of Celgene includes 585 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category. Additionally, Celgene has registered 342 trademarks with the most popular class being 'Pharmaceutical, veterinary and sanitary products'. Celgene has made 55 investments. One of their investments was on Feb 7, 2019, when they invested $60.8M in HiberCell.

Timeline

January 3, 2019
In the first major pharmaceutical deal of the year, Bristol-Myers Squibb said on Thursday that it would buy Celgene, which makes cancer drugs, in a cash-and-stock deal valued at $74 billion.
January 2019
Celgene agrees to pay up to $7 billion for the biotechnology company Impact Biomedicines, to enter market for blood-disease drugs.
2017
Celgene agrees to pay $280 million to settle claims that it marketed Thalomid and Revlimid for unapproved uses.
February 22, 2011
Celgene raises a $12,400,000 series B round.
August 1, 2009
Celgene raises a $7,250,000 series A round from Kraft Group.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Emmy Lucas
September 20, 2021
FierceBiotech
Jeffrey Stafford and his team of industry veterans have seen their biotechs go on to be acquired by the likes of Genentech, Bristol Myers Squibb and Celgene. Now, the collective is ready for its next venture: launching RNA biotech 858 Therapeutics with a $60 million series A fundraising.
Alex Keown
July 2, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
BioSpace
June 30, 2021
BioSpace
Ultragenyx Pharmaceutical Inc. today announced the appointment of Corsee Sanders, Ph.D., to the Board of Directors, effective June 29, 2021.
BioSpace
June 22, 2021
BioSpace
Infinity BiologiX, LLC (IBX), a leading next-generation central laboratory providing sample collection and processing, storage, analytical services, and scientific and technical support, has named Robin Grimwood as Chief Executive Officer.
BioSpace
June 22, 2021
BioSpace
Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic "off-the-shelf" gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Olivier Gouédard, PharmD, MBA has been appointed as Chief Operating Officer, effective immediately
Bristol Myers Squibb
June 17, 2021
www.prnewswire.com:443
/PRNewswire/ -- Silenciosamente, é assim que o câncer de rim se apresenta. Considerado o 12o tipo de câncer mais comum no mundo2, cuja prevalência é maior...
Bristol Myers Squibb
May 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Para um indivíduo acima dos 40 anos, uma dor na lombar pode representar muitos quadros. Pode ser apenas o reflexo de uma noite mal dormida,...
May 20, 2021
BioSpace
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment of Completely Resected Esophageal or Gastroesophageal Junction Cancer in Patients who have Received Neoadjuvant Chemoradiotherapy - read this article along with other careers information, tips and advice on BioSpace
BioSpace
May 4, 2021
BioSpace
Graphite Bio, Inc. , a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointments of Dr. Kristen Hege, Smital Shah and Dr. Jo Viney to its board of directors.
BioSpace
April 28, 2021
BioSpace
Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic "off-the-shelf" gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that Stanley R. Frankel, MD FACP has been appointed as Chief Medical Officer, effective immediately.
April 16, 2021
BioSpace
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma.... - read this article along with other careers information, tips and advice on BioSpace
Alex Keown
April 16, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Ben Adams
January 15, 2021
FierceBiotech
A year after Eli Lilly abruptly pulled out of an R&D pact with NextCure and its CMO left after weak trials results, the biotech is shoring up its research team with the addition of ex-Celgene exec Han Myint, M.D..
Nick Paul
January 5, 2021
FierceBiotech
Ikena Oncology has raised $120 million to advance its expanding pipeline of cancer drugs. The series B round comes as Ikena prepares to add a TEAD inhibitor to its roster of clinical programs and hustles a first-in-class KRAS asset through lead optimization.
Scopus BioPharma Inc.
December 29, 2020
www.prnewswire.com:443
/PRNewswire/ -- Scopus BioPharma Inc. (Nasdaq: SCPS) today announced the appointment of additional members to its Board of Directors. Scopus is a...
BioSpace
November 24, 2020
BioSpace
Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced Dr. Alex Lugovskoy has joined the Company as Chief Operating Officer, and that the Company has strengthened its Scientific Advisory Board with the addition of leading drug developer and clinician Dr. Rob Hershberg.
Dragonfly Therapeutics, Inc.
November 24, 2020
www.prnewswire.com:443
/PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly" or the "Company"), today announced Dr. Alex Lugovskoy has joined the Company as Chief Operating...
Mark Terry
November 9, 2020
BioSpace
Here's a look at some of the upcoming target action dates on the U.S. FDA's calendar.
November 9, 2020
BioSpace
Bristol Myers Squibb Presents Late-Breaking Phase 2 Data Demonstrating the Safety and Efficacy of Deucravacitinib (BMS-986165) in Patients with Psoriatic Arthritis - read this article along with other careers information, tips and advice on BioSpace
Heather McKenzie
November 6, 2020
BioSpace
Setbacks and delays caused by COVID-19 are making everyone, in every facet of life, nervous. This week, that includes legacy Celgene CVR investors who are staging a mass exodus as two drugs under the agreement near the deadline and one, Liso-cel, faces inspection delays.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.